» Download Public Reports
57 reports
- Company report
- December 2011
- 5 pages
- by Corporation
... For physiology or medicine. rnai therapeutics, such as "sirnas," require delivery technology to be effective systemically. Tekmira believes its lnp technology represents the most widely adopted delivery ...
December 2011
... And facilitate collaborative practice. I continue to be a member of the governance and nomination committee as well as the registrars work group for the canadian alliance of physiotherapy regulators. As part ...
November 2011
... therapeutic target, the opportunity for the development of an oral compound such as tt-301 is growing. The approach of inhibiting cytokines has multiple potential therapeutic applications for both central ...
November 2011
... A before making investment s with regard to the securities of the company. Overview transition transition is a product-focused biopharmaceutical company, developing novel therapeutics for disease ...
January 2012
... For physiology or medicine. rnai therapeutics, such as "sirnas," require delivery technology to be effective systemically. Tekmira believes its lnp technology represents the most widely adopted delivery ...
January 2012
... For physiology or medicine. rnai therapeutics, such as "sirnas," require delivery technology to be effective systemically. Tekmira believes its lnp technology represents the most widely adopted delivery ...
September 2012
... The 2006 nobel prize for physiology or medicine. rnai therapeutics, such as "sirnas," require delivery technology to be effective systemically. Tekmira believes its lnp technology represents the most ...
June 2012
... Of manitoba (cpm) serves the public interest by ensuring the ongoing pursuit of excellence in the quality of physiotherapy services in manitoba. Cpm assures the public of a trusted, fair and responsive ...
March 2012
... Awarded the 2006 nobel prize for physiology or medicine. rnai therapeutics, such as "sirnas," require delivery technology to be effective systemically. Tekmira believes its lnp technology represents ...
September 2012
... The discoves of rnai, a gene silencing mechanism used by all cells, were awarded the 2006 nobel prize for physiology or medicine. rnai therapeutics, such as "sirnas," require delivery technology to be effective ...
» Purchase Premium Reports
(From $ 250 - $ 2 000)
About 100 reports
- $ 2 000
- Company report
- March 2013
- by Global Markets Direct
Other Dermatological Disorders - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Other Dermatological Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic ...
February 2013
$ 2 000
Kidney Fibrosis - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Kidney Fibrosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides ...
March 2013
$ 300
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...
April 2013
$ 250
Summary AIM Therapeutics Inc. (AIM) is a biopharmaceutical company, based in Canada. The company discovers and develops the breakthrough medical treatments for patients with immune and inflammatory disorders. ...
April 2013
$ 250
Summary Alethia BioTherapeutics, Inc. (Alethia) is a biotechnology company. It discovers and develops monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal ...
April 2013
$ 250
Summary Aegera Therapeutics Inc. (Aegera) is a healthcare company, based in Canada. It develops targeted therapeutics to meet the medical needs. The company focuses on preclinical and early-stage clinical ...
March 2013
$ 250
Summary QLT Inc. (QLT) is a biotechnology company engaged in the development and commercialization of innovative therapies in the field of ophthalmology. The company's products are based on three unique ...
